BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manns MP, von Hahn T. Novel therapies for hepatitis C — one pill fits all? Nat Rev Drug Discov 2013;12:595-610. [DOI: 10.1038/nrd4050] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 15.6] [Reference Citation Analysis]
Number Citing Articles
1 He Y, Huang M, Tang C, Yue Y, Liu X, Zheng Z, Dong H, Liu D. Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels. Virus Res 2021;298:198404. [PMID: 33775754 DOI: 10.1016/j.virusres.2021.198404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a “special population”? World J Hepatol 2015; 7(15): 1936-1952 [PMID: 26244068 DOI: 10.4254/wjh.v7.i15.1936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
3 Qi H, Olson CA, Wu NC, Ke R, Loverdo C, Chu V, Truong S, Remenyi R, Chen Z, Du Y, Su SY, Al-Mawsawi LQ, Wu TT, Chen SH, Lin CY, Zhong W, Lloyd-Smith JO, Sun R. A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. PLoS Pathog 2014;10:e1004064. [PMID: 24722365 DOI: 10.1371/journal.ppat.1004064] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
4 Wang HL, Lu X, Yang X, Xu N. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:45-52. [PMID: 27597318 DOI: 10.1111/jgh.13587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
5 Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS One 2015;10:e0145622. [PMID: 26699619 DOI: 10.1371/journal.pone.0145622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Mauss S, Rossol S. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial. J Viral Hepat 2016;23:105-15. [PMID: 26411532 DOI: 10.1111/jvh.12471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Yang S, K R J, Lim S, Choi TG, Kim JH, Akter S, Jang M, Ahn HJ, Kim HY, Windisch MP, Khadka DB, Zhao C, Jin Y, Kang I, Ha J, Oh BC, Kim M, Kim SS, Cho WJ. Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections. J Med Chem 2015;58:9546-61. [PMID: 26613291 DOI: 10.1021/acs.jmedchem.5b01064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
8 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420. [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003] [Cited by in Crossref: 600] [Cited by in F6Publishing: 564] [Article Influence: 66.7] [Reference Citation Analysis]
9 Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther 2015;145:92-102. [PMID: 25200121 DOI: 10.1016/j.pharmthera.2014.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
10 Rosenquist Å, Samuelsson B, Johansson P, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, Horvath A, Kalmeijer R, de la Rosa G, Beumont-mauviel M. Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. J Med Chem 2014;57:1673-93. [DOI: 10.1021/jm401507s] [Cited by in Crossref: 136] [Cited by in F6Publishing: 114] [Article Influence: 17.0] [Reference Citation Analysis]
11 Morel V, Duverlie G, Brochot E. Patients eligible for treatment with simeprevir in a French center. J Clin Virol 2014;61:149-51. [PMID: 25027573 DOI: 10.1016/j.jcv.2014.06.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
12 Todt D, François C, Anggakusuma, Behrendt P, Engelmann M, Knegendorf L, Vieyres G, Wedemeyer H, Hartmann R, Pietschmann T, Duverlie G, Steinmann E. Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents Chemother 2016;60:2132-9. [PMID: 26787701 DOI: 10.1128/AAC.02427-15] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
13 Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C, Chang T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C, Sievert W, Bronowicki J, Thabut D, Lee Y, Kao J, Mcphee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. The Lancet 2014;384:1597-605. [DOI: 10.1016/s0140-6736(14)61059-x] [Cited by in Crossref: 248] [Cited by in F6Publishing: 121] [Article Influence: 31.0] [Reference Citation Analysis]
14 Lazerwith SE, Lew W, Zhang J, Morganelli P, Liu Q, Canales E, Clarke MO, Doerffler E, Byun D, Mertzman M, Ye H, Chong L, Xu L, Appleby T, Chen X, Fenaux M, Hashash A, Leavitt SA, Mabery E, Matles M, Mwangi JW, Tian Y, Lee Y, Zhang J, Zhu C, Murray BP, Watkins WJ. Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection. J Med Chem 2014;57:1893-901. [DOI: 10.1021/jm401420j] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
15 Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res 2016;5:2061. [PMID: 27746906 DOI: 10.12688/f1000research.9114.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Cheng YQ, Ren JP, Zhao J, Wang JM, Zhou Y, Li GY, Moorman JP, Yao ZQ. MicroRNA-155 regulates interferon-γ production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection. Immunology. 2015;145:485-497. [PMID: 25772938 DOI: 10.1111/imm.12463] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
17 Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 2018;57:911-928. [PMID: 29353349 DOI: 10.1007/s40262-017-0624-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
18 Watanabe T, Joko K, Seike H, Michitaka K, Horiike N, Kisaka Y, Tanaka Y, Nakanishi S, Nakanishi K, Nonaka T, Yamauchi K, Onji M, Ohno Y, Tokumoto Y, Hirooka M, Abe M, Hiasa Y. Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. Springerplus 2016;5:518. [PMID: 27186482 DOI: 10.1186/s40064-016-2190-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Stahmeyer JT, Rossol S, Krauth C. Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. J Comp Eff Res 2015;4:267-77. [PMID: 25960028 DOI: 10.2217/cer.15.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
20 Itzel T, Neubauer M, Ebert M, Evert M, Teufel A. Hepamine - A Liver Disease Microarray Database, Visualization Platform and Data-Mining Resource. Sci Rep 2020;10:4760. [PMID: 32179762 DOI: 10.1038/s41598-020-61508-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting. Clinicoecon Outcomes Res 2016;8:591-7. [PMID: 27789966 DOI: 10.2147/CEOR.S108288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Kishida Y, Imaizumi N, Tanimura H, Kashiwamura S, Kashiwagi T. A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection. Int J Mol Sci 2016;17:350. [PMID: 27005617 DOI: 10.3390/ijms17030350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Manns MP, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J Viral Hepat 2015;22:366-75. [PMID: 25363449 DOI: 10.1111/jvh.12346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
24 Abrams RPM, Solis J, Nath A. Therapeutic Approaches for Zika Virus Infection of the Nervous System. Neurotherapeutics 2017;14:1027-48. [PMID: 28952036 DOI: 10.1007/s13311-017-0575-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
25 Bell TM, Espina V, Senina S, Woodson C, Brahms A, Carey B, Lin SC, Lundberg L, Pinkham C, Baer A, Mueller C, Chlipala EA, Sharman F, de la Fuente C, Liotta L, Kehn-Hall K. Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis. Antiviral Res 2017;143:162-75. [PMID: 28442428 DOI: 10.1016/j.antiviral.2017.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
26 Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S, Sarrazin C, von Hahn T. Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cell Mol Gastroenterol Hepatol 2015;1:285-294.e1. [PMID: 28210681 DOI: 10.1016/j.jcmgh.2015.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Mish MR, Cho A, Kirschberg T, Xu J, Sebastian Zonte C, Fenaux M, Park Y, Babusis D, Feng JY, Ray AS, Kim CU. Preparation and biological evaluation of 1′-cyano-2′-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters 2014;24:3092-5. [DOI: 10.1016/j.bmcl.2014.05.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
28 Dahl SL, Kalita MM, Fischer WB. Interaction of antivirals with a heptameric bundle model of the p7 protein of hepatitis C virus. Chem Biol Drug Des 2018;91:942-50. [DOI: 10.1111/cbdd.13162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Teufel A. Bioinformatics and database resources in hepatology. Journal of Hepatology 2015;62:712-9. [DOI: 10.1016/j.jhep.2014.10.036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
30 Bourke NM, O'Neill MT, Sarwar S, Norris S, Stewart S, Hegarty JE, Stevenson NJ, O'Farrelly C. In vitro blood cell responsiveness to IFN-α predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients. J Transl Med 2014;12:206. [PMID: 25048205 DOI: 10.1186/1479-5876-12-206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Nakamura Y, Hirooka M, Abe M, Hiasa Y. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. J Med Virol. 2020;. [PMID: 32374470 DOI: 10.1002/jmv.25984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Gerold G, Pietschmann T. Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. Curr Hepat Rep 2013;12:200-13. [PMID: 32214912 DOI: 10.1007/s11901-013-0187-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Belema M, Nguyen VN, Romine JL, St. Laurent DR, Lopez OD, Goodrich JT, Nower PT, O’boyle DR, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang Y, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB. Hepatitis C Virus NS5A Replication Complex Inhibitors. Part 6: Discovery of a Novel and Highly Potent Biarylimidazole Chemotype with Inhibitory Activity Toward Genotypes 1a and 1b Replicons. J Med Chem 2014;57:1995-2012. [DOI: 10.1021/jm4016203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
34 Konreddy AK, Toyama M, Ito W, Bal C, Baba M, Sharon A. Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues. ACS Med Chem Lett 2014;5:259-63. [PMID: 24900815 DOI: 10.1021/ml400432f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
35 Scola PM, Wang AX, Good AC, Sun L, Combrink KD, Campbell JA, Chen J, Tu Y, Sin N, Venables BL, Sit S, Chen Y, Cocuzza A, Bilder DM, D’andrea S, Zheng B, Hewawasam P, Ding M, Thuring J, Li J, Hernandez D, Yu F, Falk P, Zhai G, Sheaffer AK, Chen C, Lee MS, Barry D, Knipe JO, Li W, Han Y, Jenkins S, Gesenberg C, Gao Q, Sinz MW, Santone KS, Zvyaga T, Rajamani R, Klei HE, Colonno RJ, Grasela DM, Hughes E, Chien C, Adams S, Levesque PC, Li D, Zhu J, Meanwell NA, Mcphee F. Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. J Med Chem 2014;57:1708-29. [DOI: 10.1021/jm401840s] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
36 Manfroni G, Manvar D, Barreca ML, Kaushik-Basu N, Leyssen P, Paeshuyse J, Cannalire R, Iraci N, Basu A, Chudaev M, Zamperini C, Dreassi E, Sabatini S, Tabarrini O, Neyts J, Cecchetti V. New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors. J Med Chem 2014;57:3247-62. [PMID: 24654886 DOI: 10.1021/jm401688h] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
37 Herzer K, Gerken G. Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol 2015; 7(3): 532-538 [PMID: 25848476 DOI: 10.4254/wjh.v7.i3.532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
38 Liu S, Zhang Q, Shao X, Wang W, Zhang C, Jin Z. An immunosuppressive function of interleukin-35 in chronic hepatitis C virus infection. Int Immunopharmacol 2017;50:87-94. [PMID: 28644966 DOI: 10.1016/j.intimp.2017.06.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
39 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49:136-146. [PMID: 30335208 DOI: 10.1111/hepr.13278] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
40 Boehm K, Berger B, Weger U, Heusser P. Does the model of additive effect in placebo research still hold true? A narrative review. JRSM Open 2017;8:2054270416681434. [PMID: 28321318 DOI: 10.1177/2054270416681434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
41 Belfrage AK, Abdurakhmanov E, Kerblom E, Brandt P, Oshalim A, Gising J, Skogh A, Neyts J, Danielson UH, Sandström A. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease. Bioorg Med Chem 2016;24:2603-20. [PMID: 27160057 DOI: 10.1016/j.bmc.2016.03.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Wang L, Cao D, Wang L, Zhao J, Nguyen LN, Dang X, Ji Y, Wu XY, Morrison ZD, Xie Q, El Gazzar M, Ning S, Moorman JP, Yao ZQ. HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function. Cell Discov 2018;4:51. [PMID: 30210805 DOI: 10.1038/s41421-018-0052-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
43 Tacke F, Günther R, Buggisch P, Klinker H, Schober A, John C, Lutz T, Pfeiffer-Vornkahl H, Niederau C, Cornberg M, Sarrazin C, Mauss S. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int 2017;37:205-11. [PMID: 27428297 DOI: 10.1111/liv.13206] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
44 Lasfar A, Zloza A, Cohen-Solal KA. IFN-lambda therapy: current status and future perspectives. Drug Discov Today 2016;21:167-71. [PMID: 26552337 DOI: 10.1016/j.drudis.2015.10.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
45 Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR 2nd, Sun JH, Wang C, Fridell RA, Meanwell NA. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57:1643-1672. [PMID: 24621191 DOI: 10.1021/jm401793m] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
46 Adeboyejo K, Grosche VR, José DP, Ferreira GM, Shimizu JF, King BJ, Tarr AW, Soares MMCN, Ball JK, Mcclure CP, Jardim ACG. Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000326] [Reference Citation Analysis]
47 Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol 2014;88:10584-97. [PMID: 24990994 DOI: 10.1128/JVI.01402-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
48 Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 2016;27:1467-74. [PMID: 27226385 DOI: 10.1093/annonc/mdw219] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
49 Llerena S, Cabezas J, Iruzubieta P, Crespo J. Resistance to hepatitis C virus. Implications and therapeutic options. Gastroenterol Hepatol 2017;40:484-94. [PMID: 28647053 DOI: 10.1016/j.gastrohep.2017.04.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Shibata C, Ohno M, Otsuka M, Kishikawa T, Goto K, Muroyama R, Kato N, Yoshikawa T, Takata A, Koike K. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 2014;462-463:42-8. [PMID: 25092460 DOI: 10.1016/j.virol.2014.05.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
51 Ahola T, Couderc T, Ng LF, Hallengärd D, Powers A, Lecuit M, Esteban M, Merits A, Roques P, Liljeström P. Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis 2015;15:250-7. [PMID: 25897811 DOI: 10.1089/vbz.2014.1681] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
52 Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis 2016;16:735-45. [PMID: 27301929 DOI: 10.1016/S1473-3099(16)00120-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
53 Lohmann V, Bartenschlager R. On the History of Hepatitis C Virus Cell Culture Systems: Miniperspective. J Med Chem 2014;57:1627-42. [DOI: 10.1021/jm401401n] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 7.1] [Reference Citation Analysis]
54 Nguyen Thi Thu P, Ngo Thi Quynh M, Pham Van L, Nguyen Van H, Nguyen Thanh H, Tsai F. Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6054677] [Reference Citation Analysis]
55 Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-16013 [PMID: 25473152 DOI: 10.3748/wjg.v20.i43.15992] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
56 Hardtke S, Wiebner B, Manns MP. [From the national competence network for viral hepatitis (HepNet) emerged the German Liver Foundation (Deutsche Leberstiftung)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2016;59:482-8. [PMID: 26942931 DOI: 10.1007/s00103-016-2319-6] [Reference Citation Analysis]
57 Harikishore A, Li E, Lee JJ, Cho NJ, Yoon HS. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Mol Divers 2015;19:529-39. [PMID: 25862642 DOI: 10.1007/s11030-015-9591-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Thakuri BKC, Zhang J, Zhao J, Nguyen LN, Nguyen LNT, Schank M, Khanal S, Dang X, Cao D, Lu Z, Wu XY, Jiang Y, El Gazzar M, Ning S, Wang L, Moorman JP, Yao ZQ. HCV-Associated Exosomes Upregulate RUNXOR and RUNX1 Expressions to Promote MDSC Expansion and Suppressive Functions through STAT3-miR124 Axis. Cells 2020;9:E2715. [PMID: 33353065 DOI: 10.3390/cells9122715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
59 Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 2014;58:2781-97. [PMID: 24590484 DOI: 10.1128/AAC.02386-13] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
60 Croft SL. Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration. Genome Biol 2016;17:46. [PMID: 26975569 DOI: 10.1186/s13059-016-0916-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
61 Tiwari G, Pandey V, Ojha RP. Prediction of drug-binding sites in HCV NS5B polymerase: MD simulation study. Emerging Materials Research 2017;6:239-48. [DOI: 10.1680/jemmr.15.00057] [Reference Citation Analysis]
62 Hart GR, Ferguson AL. Empirical fitness models for hepatitis C virus immunogen design. Phys Biol 2015;12:066006. [PMID: 26599153 DOI: 10.1088/1478-3975/12/6/066006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
63 Gronert Álvarez A, Fytili P, Suneetha PV, Kraft AR, Brauner C, Schlue J, Krech T, Lehner F, Meyer-Heithuis C, Jaeckel E, Klempnauer J, Manns MP, Cornberg M, Wedemeyer H. Comprehensive phenotyping of regulatory T cells after liver transplantation. Liver Transpl 2015;21:381-95. [PMID: 25451888 DOI: 10.1002/lt.24050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
64 Abu Bakar F, Ng LFP. Nonstructural Proteins of Alphavirus-Potential Targets for Drug Development. Viruses 2018;10:E71. [PMID: 29425115 DOI: 10.3390/v10020071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
65 Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414-426. [PMID: 24907224 DOI: 10.1016/s0140-6736(14)60538-9] [Cited by in Crossref: 272] [Cited by in F6Publishing: 122] [Article Influence: 34.0] [Reference Citation Analysis]
66 Gallego P, Rojas Á, Falcón G, Carbonero P, García-Lozano MR, Gil A, Grande L, Cremades O, Romero-Gómez M, Bautista JD, Del Campo JA. Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication. Food Funct 2019;10:3758-67. [PMID: 31179460 DOI: 10.1039/c9fo00733d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
67 Gable JE, Acker TM, Craik CS. Current and potential treatments for ubiquitous but neglected herpesvirus infections. Chem Rev 2014;114:11382-412. [PMID: 25275644 DOI: 10.1021/cr500255e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
68 Koutsoudakis G, Romero-Brey I, Berger C, Pérez-Vilaró G, Monteiro Perin P, Vondran FW, Kalesse M, Harmrolfs K, Müller R, Martinez JP, Pietschmann T, Bartenschlager R, Brönstrup M, Meyerhans A, Díez J. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. J Hepatol 2015;63:813-21. [PMID: 26070407 DOI: 10.1016/j.jhep.2015.06.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
69 Ding K, Wang A, Boerneke MA, Dibrov SM, Hermann T. Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site. Bioorg Med Chem Lett 2014;24:3113-7. [PMID: 24856063 DOI: 10.1016/j.bmcl.2014.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
70 Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol 2016;22:432-8. [PMID: 28081594 DOI: 10.3350/cmh.2016.0107] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
71 Ciotti M, D'Agostini C, Marrone A. Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Res 2013;6:161-70. [PMID: 27785248 DOI: 10.4021/gr576e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Wang F, Chen C, Tan W, Yang K, Yang H. Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design. Sci Rep 2016;6:22677. [PMID: 26948040 DOI: 10.1038/srep22677] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 13.3] [Reference Citation Analysis]
73 El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J 2020;72:37. [PMID: 32613565 DOI: 10.1186/s43044-020-00070-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Ochi H, Hiraoka A, Yagi S, Yukimoto A, Hirooka M, Abe M, Hiasa Y. AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. BMC Cancer 2021;21:699. [PMID: 34126947 DOI: 10.1186/s12885-021-08401-7] [Reference Citation Analysis]
75 Li GY, Zhou Y, Ying RS, Shi L, Cheng YQ, Ren JP, Griffin JW, Jia ZS, Li CF, Moorman JP, Yao ZQ. Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6. Hepatology 2015;61:1163-73. [PMID: 25477247 DOI: 10.1002/hep.27634] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
76 Yang CH, Li HC, Ku TS, Wu PC, Yeh YJ, Cheng JC, Lin TY, Lo SY. Hepatitis C virus down-regulates SERPINE1/PAI-1 expression to facilitate its replication. J Gen Virol 2017;98:2274-86. [PMID: 28857040 DOI: 10.1099/jgv.0.000901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
77 Ruggieri V, Mazzoccoli C, Pazienza V, Andriulli A, Capitanio N, Piccoli C. Hepatitis C virus, mitochondria and auto/mitophagy: Exploiting a host defense mechanism. World J Gastroenterol 2014; 20(10): 2624-2633 [PMID: 24627598 DOI: 10.3748/wjg.v20.i10.2624] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
78 Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
79 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
80 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
81 Haese N, Powers J, Streblow DN. Small Molecule Inhibitors Targeting Chikungunya Virus. Berlin: Springer Berlin Heidelberg; 2020. [DOI: 10.1007/82_2020_195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Liu B, Chen S, Guan Y, Chen L. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients. PLoS One 2015;10:e0133800. [PMID: 26193702 DOI: 10.1371/journal.pone.0133800] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
83 Bhakat S, Delang L, Kaptein S, Neyts J, Leyssen P, Jayaprakash V. Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus. RSC Adv 2015;5:85938-49. [DOI: 10.1039/c5ra14469h] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
84 Saenz V, Mazzanti di Ruggiero MDLA. Propuestas bioéticas frente a los problemas sociales y éticos que generan las enfermedades infecciosas desatendidas. pers bioet 2019;23:84-110. [DOI: 10.5294/pebi.2019.23.1.6] [Reference Citation Analysis]
85 Chen X, Yang K, Wu C, Chen C, Hu C, Buzovetsky O, Wang Z, Ji X, Xiong Y, Yang H. Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease. Cell Res 2016;26:1260-3. [PMID: 27752039 DOI: 10.1038/cr.2016.116] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
86 Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol. 2015;50:261-272. [PMID: 25270965 DOI: 10.1007/s00535-014-1000-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
87 Moradpour D, Grakoui A, Manns MP. Future landscape of hepatitis C research - Basic, translational and clinical perspectives. J Hepatol. 2016;65:S143-S155. [PMID: 27641984 DOI: 10.1016/j.jhep.2016.07.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
88 Anggakusuma, Romero-brey I, Berger C, Colpitts CC, Boldanova T, Engelmann M, Todt D, Perin PM, Behrendt P, Vondran FW, Xu S, Goffinet C, Schang LM, Heim MH, Bartenschlager R, Pietschmann T, Steinmann E. Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology 2015;62:702-14. [DOI: 10.1002/hep.27913] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
89 van Buuren N, Tellinghuisen TL, Richardson CD, Kirkegaard K. Transmission genetics of drug-resistant hepatitis C virus. Elife 2018;7:e32579. [PMID: 29589830 DOI: 10.7554/eLife.32579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Schønning K. Comparison of the QIAGEN artus HCV QS-RGQ test with the Roche COBAS Ampliprep/COBAS TaqMan HCV test v2.0 for the quantification of HCV-RNA in plasma samples. J Clin Virol 2014;60:323-7. [PMID: 24894603 DOI: 10.1016/j.jcv.2014.05.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
91 Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A. Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep 2015;32:29-48. [PMID: 25315648 DOI: 10.1039/c4np00085d] [Cited by in Crossref: 92] [Cited by in F6Publishing: 50] [Article Influence: 13.1] [Reference Citation Analysis]
92 Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin Pharmacother. 2014;15:711-716. [PMID: 24517400 DOI: 10.1517/14656566.2014.889116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
93 Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515-523. [PMID: 24209977 DOI: 10.1016/s0140-6736(13)62121-2] [Cited by in Crossref: 397] [Cited by in F6Publishing: 191] [Article Influence: 44.1] [Reference Citation Analysis]
94 Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016;31:1860-1867. [PMID: 27003037 DOI: 10.1111/jgh.13379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
95 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Nonaka T, Yamauchi K, Hirooka M, Abe M, Hiasa Y. Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2. J Med Virol 2017;89:1567-73. [PMID: 28165154 DOI: 10.1002/jmv.24776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
96 Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015; 7(10): 1377-1389 [PMID: 26052383 DOI: 10.4254/wjh.v7.i10.1377] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 10.9] [Reference Citation Analysis]
97 Chia CSB, Xu W, Shuyi Ng P. A Patent Review on SARS Coronavirus Main Protease (3CLpro ) Inhibitors. ChemMedChem 2021. [PMID: 34651447 DOI: 10.1002/cmdc.202100576] [Reference Citation Analysis]
98 Stukalov A, Pichlmair A. Gambling with Flu: "All in" to Maximize Reward. Cell Host Microbe 2015;18:643-5. [PMID: 26651939 DOI: 10.1016/j.chom.2015.11.010] [Reference Citation Analysis]
99 Stelzl E, Appel HM, Mehta R, Marins EG, Berg J, Paar C, Zurl H, Santner BI, Kessler HH. Evaluation of the new cobas® HCV genotyping test based on real-time PCRs of three different HCV genome regions. Clin Chem Lab Med 2017;55:517-21. [PMID: 27740913 DOI: 10.1515/cclm-2016-0620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
100 Griffin S. "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic? Future Med Chem 2014;6:1893-907. [PMID: 25495983 DOI: 10.4155/fmc.14.121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
101 Trivella JP, Gutierrez J, Martin P. Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C. Expert Opin Pharmacother 2015;16:617-24. [PMID: 25665437 DOI: 10.1517/14656566.2015.1012493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
102 Carrozzo M. Hepatitis C virus: a silent killer relevant to dentistry. Oral Dis 2014;20:425-9. [PMID: 24666473 DOI: 10.1111/odi.12240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Ren JP, Ying RS, Cheng YQ, Wang L, El Gazzar M, Li GY, Ning SB, Moorman JP, Yao ZQ. HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepat 2016;23:755-66. [PMID: 27004559 DOI: 10.1111/jvh.12537] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
104 Shalom-Elazari H, Zazrin-Greenspon H, Shaked H, Chill JH. Global fold and backbone dynamics of the hepatitis C virus E2 glycoprotein transmembrane domain determined by NMR. Biochim Biophys Acta 2014;1838:2919-28. [PMID: 25109935 DOI: 10.1016/j.bbamem.2014.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
105 Thakuri BKC, Zhang J, Zhao J, Nguyen LN, Nguyen LNT, Khanal S, Cao D, Dang X, Schank M, Wu XY, Morrison ZD, Gazzar ME, Li Z, Jiang Y, Ning S, Wang L, Moorman JP, Yao ZQ. LncRNA HOTAIRM1 promotes MDSC expansion and suppressive functions through the HOXA1-miR124 axis during HCV infection. Sci Rep 2020;10:22033. [PMID: 33328510 DOI: 10.1038/s41598-020-78786-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Costa R, Todt D, Zapatero-Belinchón F, Schenk C, Anastasiou OE, Walker A, Hertel B, Timmer L, Bojkova D, Ruckert M, Sarrazin C, Timm J, Lohmann V, Manns MP, Steinmann E, von Hahn T, Ciesek S. SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. J Hepatol 2019;70:603-14. [PMID: 30472319 DOI: 10.1016/j.jhep.2018.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
107 Hu Z, Liu Y, Qiu L, Fan Z, Nie W, Liang S, Jin R. Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b. Virol J 2014;11:148. [PMID: 25128407 DOI: 10.1186/1743-422X-11-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
108 García-Nicolás O, V'kovski P, Vielle NJ, Ebert N, Züst R, Portmann J, Stalder H, Gaschen V, Vieyres G, Stoffel M, Schweizer M, Summerfield A, Engler O, Pietschmann T, Todt D, Alves MP, Thiel V, Pfaender S. The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrob Agents Chemother 2018;62:e01206-18. [PMID: 30181371 DOI: 10.1128/AAC.01206-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
109 Alexandre F, Brandt G, Caillet C, Chaves D, Convard T, Derock M, Gloux D, Griffon Y, Lallos L, Leroy F, Liuzzi M, Loi A, Moulat L, Musiu C, Parsy C, Rahali H, Roques V, Seifer M, Standring D, Surleraux D. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease. Bioorganic & Medicinal Chemistry Letters 2015;25:3984-91. [DOI: 10.1016/j.bmcl.2015.07.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
110 Mantry PS, Pathak L. Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert Rev Anti Infect Ther 2016;14:157-65. [PMID: 26567871 DOI: 10.1586/14787210.2016.1120668] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
111 Pfaender S, von Hahn T, Steinmann J, Ciesek S, Steinmann E. Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapy. Rev Med Virol 2016;26:330-9. [PMID: 27185010 DOI: 10.1002/rmv.1890] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
112 Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. AIDS Res Ther 2014;11:16. [PMID: 25006340 DOI: 10.1186/1742-6405-11-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
113 Ganta KK, Mandal A, Debnath S, Hazra B, Chaubey B. Anti-HCV Activity from Semi-purified Methanolic Root Extracts of Valeriana wallichii. Phytother Res 2017;31:433-40. [PMID: 28078810 DOI: 10.1002/ptr.5765] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
114 Doak B, Over B, Giordanetto F, Kihlberg J. Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology 2014;21:1115-42. [DOI: 10.1016/j.chembiol.2014.08.013] [Cited by in Crossref: 266] [Cited by in F6Publishing: 227] [Article Influence: 33.3] [Reference Citation Analysis]
115 Pfaender S, Brown RJ, Pietschmann T, Steinmann E. Natural reservoirs for homologs of hepatitis C virus. Emerg Microbes Infect 2014;3:e21. [PMID: 26038514 DOI: 10.1038/emi.2014.19] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
116 Klimenko K, Lyakhov S, Shibinskaya M, Karpenko A, Marcou G, Horvath D, Zenkova M, Goncharova E, Amirkhanov R, Krysko A, Andronati S, Levandovskiy I, Polishchuk P, Kuz'min V, Varnek A. Virtual screening, synthesis and biological evaluation of DNA intercalating antiviral agents. Bioorg Med Chem Lett 2017;27:3915-9. [PMID: 28666733 DOI: 10.1016/j.bmcl.2017.06.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
117 Junabeegum GR, Revikumar A, Suharabeevy S, Sugunan VS. Identification of novel inhibitors of HCV NS3 protease genotype 3 subtype B through molecular docking studies of phytochemicals from Boerhavia diffusa L. Med Chem Res 2017;26:327-34. [DOI: 10.1007/s00044-016-1745-1] [Reference Citation Analysis]
118 Keaney EP, Connolly M, Dobler M, Karki R, Honda A, Sokup S, Karur S, Britt S, Patnaik A, Raman P, Hamann LG, Wiedmann B, LaMarche MJ. 2-Alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication. Bioorg Med Chem Lett 2014;24:3714-8. [PMID: 25065492 DOI: 10.1016/j.bmcl.2014.07.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
119 Dickinson BC, Packer MS, Badran AH, Liu DR. A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun 2014;5:5352. [PMID: 25355134 DOI: 10.1038/ncomms6352] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 7.6] [Reference Citation Analysis]
120 Bobardt M, Hansson MJ, Mayo P, Ure D, Foster R, Gallay P. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice. PLoS One 2020;15:e0237236. [PMID: 32764799 DOI: 10.1371/journal.pone.0237236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
121 Ren JP, Zhao J, Dai J, Griffin JW, Wang L, Wu XY, Morrison ZD, Li GY, El Gazzar M, Ning SB, Moorman JP, Yao ZQ. Hepatitis C virus-induced myeloid-derived suppressor cells regulate T-cell differentiation and function via the signal transducer and activator of transcription 3 pathway. Immunology 2016;148:377-86. [PMID: 27149428 DOI: 10.1111/imm.12616] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
122 Jarret A, McFarland AP, Horner SM, Kell A, Schwerk J, Hong M, Badil S, Joslyn RC, Baker DP, Carrington M, Hagedorn CH, Gale M Jr, Savan R. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med 2016;22:1475-81. [PMID: 27841874 DOI: 10.1038/nm.4211] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
123 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
124 Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y, Wang H, Zhu Y, Feng L, Zhao J, Shao M, Yang X, Zhang L, Peng C, Yang K, Ma D, Rao Z, Yang H. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 2021. [PMID: 34687004 DOI: 10.1007/s13238-021-00883-2] [Reference Citation Analysis]
125 Chung CK, Cleator E, Dumas AM, Hicks JD, Humphrey GR, Maligres PE, Nolting AF, Rivera N, Ruck RT, Shevlin M. A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C. Org Lett 2016;18:1394-7. [PMID: 26950496 DOI: 10.1021/acs.orglett.6b00331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Vankadara S, Wong YX, Liu B, See YY, Tan LH, Tan QW, Wang G, Karuna R, Guo X, Tan ST, Fong JY, Joy J, Chia CSB. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors. Bioorg Med Chem Lett 2021;48:128263. [PMID: 34271072 DOI: 10.1016/j.bmcl.2021.128263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther. 2013;38:1365-1372. [PMID: 24127648 DOI: 10.1111/apt.12523] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
128 Mina MM, Herawati L, Butler T, Lloyd A. Hepatitis C in Australian prisons: a national needs assessment. Int J Prison Health 2016;12:3-16. [PMID: 26933988 DOI: 10.1108/IJPH-08-2015-0025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
129 Stöhr S, Costa R, Sandmann L, Westhaus S, Pfaender S, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, von Hahn T, Ciesek S. Host cell mTORC1 is required for HCV RNA replication. Gut 2016;65:2017-28. [PMID: 26276683 DOI: 10.1136/gutjnl-2014-308971] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
130 Watanabe T, Imamura T, Hiasa Y. Roles of protein kinase R in cancer: Potential as a therapeutic target. Cancer Sci 2018;109:919-25. [PMID: 29478262 DOI: 10.1111/cas.13551] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
131 Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014; 146: 1145-50. e1-4. [PMID: 24662488 DOI: 10.1053/j.gastro.2014.03.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
132 Chukkapalli V, Randall G. Hepatitis C virus replication compartment formation: mechanism and drug target. Gastroenterology 2014;146:1164-7. [PMID: 24675576 DOI: 10.1053/j.gastro.2014.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
133 Amako Y, Munakata T, Kohara M, Siddiqui A, Peers C, Harris M. Hepatitis C virus attenuates mitochondrial lipid β-oxidation by downregulating mitochondrial trifunctional-protein expression. J Virol. 2015;89:4092-4101. [PMID: 25673715 DOI: 10.1128/jvi.01653-14] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
134 Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Front Immunol 2018;9:3175. [PMID: 30713538 DOI: 10.3389/fimmu.2018.03175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
135 Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-743.e1. [PMID: 24262278 DOI: 10.1053/j.gastro.2013.11.007] [Cited by in Crossref: 133] [Cited by in F6Publishing: 135] [Article Influence: 14.8] [Reference Citation Analysis]
136 Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147:366-76.e6. [PMID: 24727022 DOI: 10.1053/j.gastro.2014.04.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
137 Kao J, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng C, Roberts SK, Lee Y, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int 2016;36:954-62. [DOI: 10.1111/liv.13049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
138 Hart GR, Ferguson AL. Computational design of hepatitis C virus immunogens from host-pathogen dynamics over empirical viral fitness landscapes. Phys Biol 2018;16:016004. [PMID: 30484433 DOI: 10.1088/1478-3975/aaeec0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
139 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]